BGM.US BGM Group Ltd.

Healthcare Pharmaceuticals USA Stocks
8.29 USD
Close of Nov 14, 2026
6.45 283.20
Market cap
USD 105M
P/E
-
P/B
0.26x
ROE
-2.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is BGM.US undervalued?

Graham number

The Graham number of BGM Group Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BGM Group Ltd. fundamental analysis

No fundamental analysis for BGM Group Ltd. yet.

BGM Group Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BGM Group Ltd.

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used b…

Full company profile